Primary Myelofibrosis: Update on definition, pathogenesis, and treatment

Annual Review of Medicine

Volumn 60, Issue , 2009, Pages 233-245

  Abdel Wahab, Omar I ^a   Levine, Ross L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chronic myelogenous leukemia (CML); Essential thrombocythemia (ET); Extramedullary hematopoiesis (EMH); Janus kinase 2 (JAK2); Myeloproliferative neoplasm (MPN); Polycythemia vera (PV); Primary myelofibrosis (PMF)

Indexed keywords

ANDROGEN; ANTIANEMIC AGENT; AT 9283; AURORA KINASE INHIBITOR; BUSULFAN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DANAZOL; FLUDARABINE; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; INCB 01824; ITF 2357; JANUS KINASE 2; JANUS KINASE INHIBITOR; LENALIDOMIDE; LESTAURTINIB; PREDNISONE; TG 101209; TG 101348; THALIDOMIDE; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG; XL 019;

ALLOGENEIC STEM CELL TRANSPLANTATION; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DISEASE COURSE; DROWSINESS; DRUG ACTIVITY; DRUG TOLERABILITY; FATIGUE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MORTALITY; MYELOID METAPLASIA; NEUTROPENIA; PARESTHESIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; TREATMENT RESPONSE;

HUMANS; PRIMARY MYELOFIBROSIS;

EID: 67649300979     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.60.041707.160528     Document Type: Review

References (59)

1. Dameshek W. 1951. Some speculations on the myeloproliferative syndromes. Blood 6:372-75
2. Baxter EJ, Scott LM, Campbell PJ, et al. 2005. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-61
3. James C, Ugo V, Le Couedic JP, et al. 2005. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-48
4. Kralovics R, Passamonti F, Buser AS, et al. 2005. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352:1779-90
5. Levine RL, Wadleigh M, Cools J, et al. 2005. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-97
6. Pikman Y, Lee BH, Mercher T, et al. 2006. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3:e270
7. Hueck G. 1879. Zwei Falle von Leukamie mit eigenthumlichem Blut - resp. Knochenmarksbefund. Arch. Pathol. Anat. Physiol. Virchows 78:475-96
8. Mesa RA, Verstovsek S, Cervantes F, et al. 2007. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk. Res. 31:737-40
9. Tefferi A, Thiele J, Orazi A, et al. 2007. Proposals and rationale for revision of theWorld Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110:1092-97
10. Tefferi A, Mesa RA, Schroeder G, et al. 2001. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br. J. Haematol. 113:763-71
11. Reilly JT, Snowden JA, Spearing RL, et al. 1997. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br. J. Haematol. 98:96-102
12. Amberger DM, Saleem A, Kemp BL, et al. 1990. Acute myelofibrosis - a leukemia of pluripotent stem cell. A report of three cases and review of the literature. Ann. Clin. Lab. Sci. 20:409-14
13. Verstovsek S, Silver RT, Cross NC, Tefferi A. 2006. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? Leukemia 20:2067
14. Wang YL, Vandris K, Jones A, et al. 2008. JAK2 mutations are present in all cases of polycythemia vera. Leukemia 22:1289
15. Rollison DE, Howlader N, Smith MT, et al. 2008. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001 - 2004, using data from the NAACCR and SEER programs. Blood 112:45-52
16. Visani G, Finelli C, Castelli U, et al. 1990. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br. J. Haematol. 75:4-9
17. Mesa RA, Silverstein MN, Jacobsen SJ, et al. 1999. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study, 1976-1995. Am. J. Hematol. 61:10-15
18. Koch CA, Li CY, Mesa RA, et al. 2003. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin. Proc. 78:1223-33
19. Kroger N, Mesa RA. 2008. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 22:474-86
20. Giovanni B, Michelle E, Letizia C, et al. 2002. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk. Lymphoma 43:2301-7
21. Brubaker LH, Briere J, Laszlo J, et al. 1982. Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Arch. Intern. Med. 142:1533-37
22. Dupriez B, Morel P, Demory JL, et al. 1996. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88:1013-18
23. Thiele J, Kvasnicka HM, Boeltken B, et al. 1999. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - a clinicopathological study. Leukemia 13:1741-48
24. Thiele J, Kvasnicka HM. 2004. Prefibrotic chronic idiopathic myelofibrosis-a diagnostic enigma? Acta Haematol. 111:155-59
25. Beer PA, Campbell PJ, Scott LM, et al. 2008. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112:141-49
26. Mesa RA, Li CY, Ketterling RP, et al. 2005. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 105:973-77
27. Campbell PJ, Baxter EJ, Beer PA, et al. 2006. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108:3548-55
28. Theocharides A, Boissinot M, Girodon F, et al. 2007. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110:375-79
29. Fialkow PJ, Jacobson RJ, Papayannopoulou T. 1977. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am. J. Med. 63:125-30
30. Fialkow PJ, Faguet GB, Jacobson RJ, et al. 1981. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 58:916-19
31. Asimakopoulos FA, Holloway TL, Nacheva EP, et al. 1996. Detection of chromosome 20q deletions in bone marrow metaphases but not peripheral blood granulocytes in patients with myeloproliferative disorders or myelodysplastic syndromes. Blood 87:1561-70
32. Lacout C, Pisani DF, Tulliez M, et al. 2006. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108:1652-60
33. Wernig G, Mercher T, Okabe R, et al. 2006. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107:4274-81
34. Lindauer K, Loerting T, Liedl KR, et al. 2001. Prediction of the structure of human Janus kinase 2 ( JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng. 14:27-37
35. Saharinen P, Takaluoma K, Silvennoinen O. 2000. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell Biol. 20:3387-95
36. Levine RL, Pardanani A, Tefferi A, et al. 2007. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer 7:673-83
37. Pardanani AD, Levine RL, Lasho T, et al. 2006. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108:3472-76
38. Ding J, Komatsu H, Wakita A, et al. 2004. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103:4198-200
39. Chaligne R, Tonetti C, Besancenot R, et al. 2008. New mutations of MPL in primitive myelofibrosis: only the MPLW515 mutations promote a G(1)/S-phase transition. Leukemia 22(8):1557-66
40. Funakoshi-Tago M, Pelletier S, Matsuda T, et al. 2006. Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2. EMBO J. 25:4763-72
41. Pardanani A, Fridley BL, Lasho TL, et al. 2008. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 111:2785-89
42. Tefferi A. 2005. Pathogenesis of myelofibrosis with myeloid metaplasia. J. Clin. Oncol. 23:8520-30
43. Rameshwar P, Chang VT, Thacker UF, et al. 1998. Systemic transforming growth factor-beta in patients with bone marrow fibrosis - pathophysiological implications. Am. J. Hematol. 59:133-42
44. Villeval JL, Cohen-Solal K, Tulliez M, et al. 1997. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 90:4369-83
45. Yan XQ, Lacey D, Hill D, et al. 1996. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood 88:402-9
46. Deleted in proof
47. (+) cells in myelofibrosis with myeloid metaplasia. Blood 98:3249-55
48. Soll E, Massumoto C, Clift RA, et al. 1995. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 86:4667-73
49. Guardiola P, Anderson JE, Gluckman E. 2000. Myelofibrosis with myeloid metaplasia. N. Engl. J. Med. 343:659
50. Kroeger N, Holler E, Kobbe G, et al. 2007. Dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Results from a multicenter prospective trial of the Chronic LeukemiaWorking Party of the European group for Blood and Marrow Transplantation (EBMT). Blood 110:683 (Abstr.)
51. Lofvenberg E, Wahlin A. 1988. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur. J. Haematol. 41:375-81
52. Tefferi A, Cortes J, Verstovsek S, et al. 2006. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108:1158-64
53. Huang J, Li CY, Mesa RA, et al. 2007. Erythropoiesis stimulating agents and the risk of leukemic transformation in primary myelofibrosis. Blood 110:683 (Abstr.)
54. Mesa RA, Nagorney DS, Schwager S, et al. 2006. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 107:361-70
55. Elliott MA, Chen MG, Silverstein MN, et al. 1998. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br. J. Haematol. 103:505-11
56. Tefferi A, Jimenez T, Gray LA, et al. 2001. Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. Eur. J. Haematol. 66:37-42
57. Pardanani A. 2008. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22:23-30
58. Verstovsek S, Kantarjian H, Pardanani A, et al. 2007. INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and postpolycythemia vera/essential thrombocythemia (post-PV/ET MF). Blood 110:558
59. Pardanani A, Hood J, Lasho T, et al. 2007. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21:1658-68